
Exact Sciences (EXAS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
706.8M
Gross Profit
500.5M
70.82%
Operating Income
-89.8M
-12.70%
Net Income
-101.2M
-14.32%
EPS (Diluted)
$-0.54
Balance Sheet Metrics
Total Assets
5.7B
Total Liabilities
3.3B
Shareholders Equity
2.4B
Debt to Equity
1.38
Cash Flow Metrics
Operating Cash Flow
-37.0M
Free Cash Flow
-365.0K
Revenue & Profitability Trend
Exact Sciences Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 2.8B | 2.5B | 2.1B | 1.8B | 1.5B |
Cost of Goods Sold | 840.2M | 654.2M | 574.4M | 458.8M | 354.3M |
Gross Profit | 1.9B | 1.8B | 1.5B | 1.3B | 1.1B |
Gross Margin % | 69.5% | 73.8% | 72.4% | 74.0% | 76.2% |
Operating Expenses | |||||
Research & Development | 431.2M | 425.9M | 393.4M | 385.6M | 554.1M |
Selling, General & Administrative | 1.7B | 1.6B | 1.6B | 1.7B | 1.1B |
Other Operating Expenses | -9.2M | -78.4M | 13.2M | - | -23.7M |
Total Operating Expenses | 2.1B | 2.0B | 2.0B | 2.0B | 1.6B |
Operating Income | -179.1M | -214.3M | -577.5M | -835.5M | -558.0M |
Operating Margin % | -6.5% | -8.6% | -27.7% | -47.3% | -37.4% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | - |
Interest Expense | 32.0M | 24.4M | 13.9M | 12.9M | 11.8M |
Other Non-Operating Income | -819.6M | 42.4M | -35.4M | 11.6M | -253.9M |
Pre-tax Income | -1.0B | -201.7M | -632.6M | -842.5M | -829.1M |
Income Tax | -7.3M | 2.4M | -9.1M | -246.9M | -5.5M |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -1.0B | -204.1M | -623.5M | -595.6M | -823.6M |
Net Margin % | -37.3% | -8.2% | -29.9% | -33.7% | -55.2% |
Key Metrics | |||||
EBITDA | 30.3M | -13.1M | -385.7M | -660.8M | -400.0M |
EPS (Basic) | $-5.59 | $-1.13 | $-3.54 | $-3.48 | $-5.61 |
EPS (Diluted) | $-5.59 | $-1.13 | $-3.54 | $-3.48 | $-5.61 |
Basic Shares Outstanding | 184197000 | 180144000 | 176351000 | 171348000 | 151137000 |
Diluted Shares Outstanding | 184197000 | 180144000 | 176351000 | 171348000 | 151137000 |
Income Statement Trend
Exact Sciences Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 600.9M | 605.4M | 242.5M | 315.5M | 1.5B |
Short-term Investments | 437.1M | 172.3M | 389.6M | 715.0M | 348.7M |
Accounts Receivable | 249.0M | 203.6M | 158.0M | 216.6M | 233.2M |
Inventory | 162.4M | 127.5M | 118.3M | 105.0M | 92.3M |
Other Current Assets | 122.0M | 85.6M | 73.9M | 74.1M | 33.2M |
Total Current Assets | 1.6B | 1.2B | 982.3M | 1.4B | 2.2B |
Non-Current Assets | |||||
Property, Plant & Equipment | 117.0M | 143.7M | 167.0M | 364.0M | 268.1M |
Goodwill | 5.7B | 6.6B | 6.6B | 6.8B | 3.3B |
Intangible Assets | 1.0B | 1.9B | 2.0B | 2.1B | 847.1M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 169.7M | 177.4M | 90.6M | 74.6M | 63.8M |
Total Non-Current Assets | 4.4B | 5.3B | 5.2B | 5.3B | 2.7B |
Total Assets | 5.9B | 6.5B | 6.2B | 6.7B | 4.9B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 89.6M | 78.8M | 74.9M | 67.8M | 35.7M |
Short-term Debt | 276.6M | 79.4M | 28.4M | 19.7M | 325.5M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 37.8M | 14.8M | 10.2M | 31.0M | 38.3M |
Total Current Liabilities | 732.2M | 514.7M | 412.7M | 517.1M | 633.1M |
Non-Current Liabilities | |||||
Long-term Debt | 2.5B | 2.5B | 2.4B | 2.4B | 2.0B |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 315.5M | 336.0M | 352.5M | 417.8M | 51.3M |
Total Non-Current Liabilities | 2.8B | 2.8B | 2.8B | 2.8B | 2.1B |
Total Liabilities | 3.5B | 3.3B | 3.2B | 3.3B | 2.7B |
Equity | |||||
Common Stock | 1.9M | 1.8M | 1.8M | 1.7M | 1.6M |
Retained Earnings | -4.5B | -3.5B | -3.3B | -2.6B | -2.0B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.4B | 3.1B | 3.0B | 3.4B | 2.2B |
Key Metrics | |||||
Total Debt | 2.8B | 2.6B | 2.4B | 2.4B | 2.3B |
Working Capital | 839.2M | 679.7M | 569.5M | 909.2M | 1.6B |
Balance Sheet Composition
Exact Sciences Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -1.0B | -204.1M | -623.5M | -595.6M | -823.6M |
Depreciation & Amortization | 214.9M | 206.6M | 197.6M | 180.3M | 163.4M |
Stock-Based Compensation | 214.9M | 231.3M | 206.8M | 253.1M | 152.9M |
Working Capital Changes | -99.6M | -83.1M | 24.4M | -58.7M | -97.4M |
Operating Cash Flow | -694.9M | 87.2M | -223.8M | -268.9M | -182.0M |
Investing Activities | |||||
Capital Expenditures | -136.0M | -124.2M | -214.5M | -135.8M | -65.1M |
Acquisitions | 0 | -69.0M | -57.5M | -517.8M | -22.6M |
Investment Purchases | -466.8M | -139.9M | -131.5M | -1.2B | -1.1B |
Investment Sales | 205.8M | 383.0M | 453.1M | 794.3M | 886.7M |
Investing Cash Flow | -442.2M | 49.7M | 74.1M | -1.1B | -702.0M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 266.8M | 138.0M | 50.0M | 0 | 1.1B |
Debt Repayment | -50.0M | 0 | 0 | -23.7M | -151.3M |
Financing Cash Flow | 199.0M | 128.2M | 44.5M | -29.0M | 1.8B |
Free Cash Flow | 74.5M | 31.9M | -438.0M | -238.0M | 71.4M |
Net Change in Cash | -938.1M | 265.1M | -105.2M | -1.4B | 950.1M |
Cash Flow Trend
Exact Sciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-8.17
Forward P/E
-132.62
Price to Book
3.46
Price to Sales
2.90
PEG Ratio
0.09
Profitability Ratios
Profit Margin
-34.19%
Operating Margin
0.34%
Return on Equity
-35.51%
Return on Assets
-1.39%
Financial Health
Current Ratio
2.89
Debt to Equity
102.73
Beta
0.93
Per Share Data
EPS (TTM)
$-5.45
Book Value per Share
$13.05
Revenue per Share
$15.77
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
exas | 8.5B | -8.17 | 3.46 | -35.51% | -34.19% | 102.73 |
Thermo Fisher | 184.1B | 28.17 | 3.64 | 13.42% | 15.24% | 69.62 |
Danaher | 151.0B | 44.88 | 2.89 | 6.68% | 14.21% | 35.45 |
Charles River | 7.7B | 681.33 | 2.30 | -1.81% | -1.66% | 82.04 |
Guardant Health | 7.3B | -16.54 | -23.92 | 312.48% | -49.93% | -4.37 |
RadNet | 5.2B | 1,425.75 | 5.47 | 1.74% | -0.78% | 156.12 |
Financial data is updated regularly. All figures are in the company's reporting currency.